Piśmiennictwo

1. Bertalanffy L.V.: An outline of general system theory. Br J Philos Sci 1950; 1: 134-165.
2. Hodgkin A.L., Huxley A.F.: A quantitative description of membrane current and its application to conduction and excitation in nerve. J Physiol 1952; 117: 500-544.
3. Noble D.: Cardiac action and pacemaker potentials based on the Hodgkin-Huxley equations. Nature 1960; 188: 495-497.
4. Weston A.D., Hood L.: Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res 2004; 3: 179-196.
5. Hood L., Perlmutter R.M.: The impact of systems approaches on biological problems in drug discovery. Nat Biotechnol 2004; 22: 1215-1217.
6. Kohl P., Noble D.: Systems biology and the virtual physiological human. Mol Syst Biol 2009; 5: 292.
7. Silver P.A., Way J.C.: Molecular systems biology in drug development. Clin Pharmacol Ther 2007; 82: 586-590.
8. Arrell D.K., Zlatkovic J., Kane G.C., Yamada S., Terzic, A.: ATP-sensitive K+ channel knockout induces cardiac proteome remodeling predictive of heart disease susceptibility. J Proteome Res 2009; 8: 4823-4834.
9. Nelson T., Behfar A., Terzic A.: Stem cells: biologics for regeneration. Clin Pharmacol Ther 2008; 84: 620-623.
10. Bartunek J., Sherman W., Vanderheyden M., Fernandez-Aviles F., Wijns W., Terzic, A.: Delivery of biologics in cardiovascular regenerative medicine. Clin Pharmacol Ther 2009; 85: 548-552.
11. Barabasi A.L., Albert R.: Emergence of scaling in random networks. Science 1999; 286: 509-512.
12. Barabasi A.L.: Scale-free networks: a decade and beyond. Science 2009; 325: 412-413.
13. Khalil I., Brewer M.A., Neyarapally T., Runowicz C.D.: The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer. Gynecol Oncol 2010; 116: 282-285.
14. Sauer U., Heinemann M., Zamboni N.: Genetics. Getting closer to the whole picture. Science 2007; 316: 550-551.
15. Ishii N., Nakahigashi K., Baba T., Robert M., Soga T., Kanai A. et al.: Multiple high-throughput analyses monitor the response of E. coli to perturbations. Science 2007; 316: 593-597.
16. Lu R., Markowetz F., Unwin R.D., Leek J.T., Airoldi E.M., MacArthur B.D. et al.: Systems-level dynamic analyses of fate change in murine embryonic stem cells. Nature 2009; 462: 358-362.
17. Luo F., Yang Y., Chen C.F., Chang R., Zhou J., Scheuermann R.H.: Modular organization of protein interaction networks. Bioinformatics 2007; 23: 207-214.
18. Goh K.I., Cusick M.E., Valle D., Childs B., Vidal M., Barabasi A.L.: The human disease network. Proc Natl Acad Sci U S A 2007; 104: 8685-8690.
19. Ozgur A., Vu T., Erkan G., Radev D.R.: Identifying gene-disease associations using centrality on a literature mined gene-interaction network. Bioinformatics 2008; 24: i277-285.
20. Berger S.I., Posner J.M., Ma'ayan A.: Genes-Networks: connecting lists of gene symbols using mammalian protein interactions databases. BMC Bioinformatics 2007; 8: 372.
21. Chen J., Aronow B.J., Jegga A.G.: Disease candidate gene identification and prioritization using protein interaction networks. BMC Bioinformatics 2009; 10: 73.
22. Kohler S., Bauer S., Horn D., Robinson P.N.: Walking the interactome for prioritization of candidate disease genes. Am J Hum Genet 2008; 82: 949-958.
23. Camargo L.M., Collura V., Rain J.C., Mizuguchi K., Hermjakob H., Kerrien S. et al.: Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol Psychiatry 2007; 12: 74-86.
24. Chu L.H., Chen B.S.: Construction of a cancer-perturbed protein-protein interaction network for discovery of apoptosis drug targets. BMC Syst Biol 2008; 2: 56.
25. Durmus Tekir S., Yalcin Arga K., Ulgen K.O.: Drug targets for tumorigenesis: insights from structural analysis of EGFR signaling network. J Biomed Inform 2009; 42: 228-236.
26. Fatumo S., Plaimas K., Mallm J.P., Schramm G., Adebiyi E., Oswald M. et al.: Estimating novel potential drug targets of Plasmodium falciparum by analysing the metabolic network of knock-out strains in silico. Infect Genet Evol 2009; 9: 351-358.
27. Hwang S., Son S.W., Kim SC., Kim Y.J., Jeong H., Lee D.: A protein interaction network associated with asthma. J Theor Biol 2008; 252: 722-731.
28. Hyduke D.R., Jarboe L.R., Tran L.M., Chou K.J., Liao J.C.: Integrated network analysis identifies nitric oxide response networks and dihydroxyacid dehydratase as a crucial target in Escherichia coli. Proc Natl Acad Sci U S A 2007; 104: 8484-8489.
29. Lim J., Hao T., Shaw C., Patel A.J., Szabo G., Rual, J.F. et al.: A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Cell 2006; 125: 801-814.
30. Raman K., Chandra N.: Mycobacterium tuberculosis interactome analysis unravels potential pathways to drug resistance. BMC Microbiol 2008; 8: 234.
31. Tanaka T., Oka T., Shimada Y., Umemoto N., Kuroyanagi J., Sakamoto C. et al.: Pharmacogenomics of cardiovascular pharmacology: pharmacogenomic network of cardiovascular disease models. J Pharmacol Sci 2008; 107: 8-14.
32. Singh S., Malik B.K., Sharma D.K.: Choke point analysis of metabolic pathways in E.histolytica: a computational approach for drug target identification. Bioinformation 2007; 2: 68-72.
33. Sridhar P., Kahveci T., Ranka S.: An iterative algorithm for metabolic network-based drug target identification. Pac Symp Biocomput 2007; 88-99.
34. Sridhar P., Song B., Kahveci T., Ranka S.: Mining metabolic networks for optimal drug targets. Pac Symp Biocomput 2008; 291-302.
35. Ruths D.A., Nakhleh L., Iyengar M.S., Reddy S.A., Ram P.T.: Hypothesis generation in signaling networks. J Comput Biol 2006; 13: 1546-1557.
36. Stites E.C., Trampont P.C., Ma Z., Ravichandran K.S.: Network analysis of oncogenic Ras activation in cancer. Science 2007; 318: 463-467.
37. Dasika M.S., Burgard A., Maranas C.D.: A computational framework for the topological analysis and targeted disruption of signal transduction networks. Biophys J 2006; 91: 382-398.
38. Hopkins A.L.: Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008; 4: 682-690.
39. Morphy R., Kay C., Rankovic Z.: From magic bullets to designed multiple ligands. Drug Discov Today 2004; 9: 641-651.
40. Leeson P.D., Springthorpe B.: The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 2007; 6: 881-890.
41. Xie L., Li J., Bourne P.E.: Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput Biol 2009; 5: e1000387.
42. Schrattenholz A., Soskic V.: What does systems biology mean for drug development? Curr Med Chem 2008; 15: 1520-1528.
43. Yang L., Xu L., He L.: A CitationRank algorithm inheriting Google technology designed to highlight genes responsible for serious adverse drug reaction. Bioinformatics 2009; 25: 2244-2250.
44. Csoka A.B., Szyf M.: Epigenetic side-effects of common pharmaceuticals: a potential new field in medicine and pharmacology. Med Hypotheses 2009; 73: 770-780.
45. Sica D.A., Brath L.: Angiotensin-converting enzyme inhibition-emerging pulmonary issues relating to cough. Congest Heart Fail 2006; 12: 223-226.
46. Cheung B.M., Cheung G.T., Lauder I.J., Lau C.P., Kumana C.R.: Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. J Hum Hypertens 2006; 20: 37-43.
47. Gonzalez-Angulo A.M., Hennessy B.T., Mills G.B.: Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol 2010; 28: 2777-2783.
48. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R. et al.: Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14: 1351-1356.
49. Massarelli E., Varella-Garcia M., Tang X., Xavier A.C., Ozburn N.C., Liu D.D. et al.: KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007; 13: 2890-2896.
50. Ihle N.T., Lemos R. Jr., Wipf P., Yacoub A., Mitchell C., Siwak D. et al.: Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 2009; 69: 143-150.
51. Jimeno A., Messersmith W.A., Hirsch F.R., Franklin W.A., Eckhardt S.G.: KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 2009; 27: 1130-1136.
52. Leary R.J., Lin J.C., Cummins J., Boca S., Wood L.D., Parsons D.W. et al.: Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A 2008; 105: 16224-16229.
53. Barabasi A.L., Oltvai Z.N.: Network biology: understanding the cell's functional organization. Nat Rev Genet 2004; 5: 101-113.
54. Merico D., Gfeller D., Bader G.D.: How to visually interpret biological data using networks. Nat Biotechnol 2009; 27: 921-924.
55. Yildirim M.A., Goh K.I., Cusick M.E., Barabasi A.L., Vidal M.: Drug-target network. Nat Biotechnol 2007; 25: 1119-1126.
56. Arrell D.K., Terzic A.: Network systems biology for drug discovery. Clin Pharmacol Ther 2010; 88: 120-125.
57. Berger S.I., Iyengar R.: Role of systems pharmacology in understanding drug adverse events. Wiley Interdiscip Rev Syst Biol Med 2011; 3: 129-135.
58. Faustino R.S., Terzic A.: Bioinformatic networks: molecular reticles for pinpointing pharmacological target selection. Clin Pharmacol Ther 2008; 84: 543-545.
59. Arrell D.K., Niederlander N.J., Perez-Terzic C., Chung S., Behfar A., Terzic A.: Pharmacoproteomics: advancing the efficacy and safety of regenerative therapeutics. Clin Pharmacol Ther 2007; 82: 316-319.